Vestibular Socket Therapy Using Magnesium Membrane Versus Cortical Lamina for Immediate Im
This randomized controlled clinical trial evaluates the effectiveness of bioresorbable magnesium membranes compared to traditional cortical lamina in Vestibular Socket Therapy (VST) for immediate implant placement in Type II extraction sockets. The study utilizes Vestibular Socket Therapy (VST), a minimally invasive te
| Condition(s) | Immediate Dental Implant in Type 2 Extraction Socket, Vestibular Socket Therapy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This randomized controlled clinical trial evaluates the effectiveness of bioresorbable magnesium membranes compared to traditional cortical lamina in Vestibular Socket Therapy (VST) for immediate implant placement in Type II extraction sockets. The study utilizes Vestibular Socket Therapy (VST), a minimally invasive technique that involves a small incision and a subperiosteal tunnel to place a "bone shield" and graft without the need to raise a traditional flap. The trial compares two distinct materials used as the regenerative barrier: the control group utilizes a cortical lamina, which is a rigid bone plate known for its stability and slow resorption rate. The experimental group receives a magnesium membrane, an emerging class of "bioresorbable metals" that provides mechanical stability |
| Who can participate | Inclusion Criteria: * Single or multiple teeth with hopeless prognosis in maxillary anterior teeth with either type I or type II extraction sockets. * Deficient labial bone plate in width (type I) and height (type II) sockets. * Minimal of 3.0 mm basal bone present for immediate implant placement to achieve optimum primary stability. Exclusion Criteria: * Current smokers. * Patients with debilitating systemic disease. * Patients who have undergone any sort of radiotherapy and chemotherapy in past 2 years. * Pregnant and Lactating females. |
| Sex | All |
| Lead sponsor | Mohamed Adel Alfeky |
| Locations | Giza, Egypt |
| Start date | 2026-03-12 |
| NCT ID | NCT07526272 |
| Official listing | https://clinicaltrials.gov/study/NCT07526272 |